Corporate broker WH Ireland (WHI) used a piece of important news flow to re-look at the potential and valuations of the NetScientific PLC (AIM:NSCI)’s (NSCI) investments.
On Tuesday, NSCI investee company PDS Biotechnology Corporation (NASDAQ:PDSB) inked a licence deal with Merck KGaA worth an upfront US$5mln.
hVIVO PLC (AIM:HVO) is well placed to exceed 2023 revenue forecasts, according to the company’s corporate broker, finnCap.
The comment followed the research group’s latest contract – a £5.2mln deal to test a vaccine candidate on behalf of an unnamed Asia-Pacific-based drug developer.
Arecor Therapeutics PLC (AIM:AREC)'s subsidiary, Tetris Pharma, has launched in Austria its emergency injector that treats severe, low blood sugar levels in diabetics.
Ogluo is a glucagon-filled ready-to-use pen that treats hypoglycemia in both children and adults.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) said it will unveil three strategic collaborations at the CES 2023 technology event in Las Vegas that starts on Thursday, where it has booked a private suite to show off its latest FOVIO software and algorithm developments.
One is a partnership with industry leaders Ambarella Inc and Autobrains for a “streamlined solution” for automotive manufacturers that combines advanced driver assistance system (ADAS) and driver monitoring systems (DMS), using a single system-on-chip (SoC) and multiple cameras.
Contract research specialist hVIVO PLC said it has signed a £5.2mln contract with a biotech company in the Asia Pacific region to test the latter's respiratory syncytial virus (RSV) vaccine candidate.
The phase IIa clinical trial will be held at the company's London facilities and will assess the drug's safety, its ability to provoke an immune response (immunogenicity), and efficacy.
Oriole Resources Plc's (AIM:ORR) senior management is extending its salary sacrifice scheme in which all directors are receiving shares instead of cash. As a result, some 2.7mln shares are now being issued, representing £7,000.